and streamline your search for investment opportunities using Tipranks' Stock Screener Jessica Fye’s rating is based on Vertex Pharmaceuticals’ strong pipeline and expected growth. The company ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Hosted on MSN14d
Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipeline stock growthWhile CF treatments drive current growth, Vertex's pipeline holds significant potential for future expansion. The company is preparing for two key drug approvals in January 2025: suzetrigine for ...
Vertex Pharmaceuticals dominates the market ... Last July, Sionna expanded its pipeline by licensing three clinical-stage CF drugs that AbbVie developed under a partnership with Galapagos.
Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally ...
While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs and potential product launches are on the horizon: 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback